OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
NEW YORK, May 25, 2017 -- The Law Offices of Vincent Wong announce that a securities action has been commenced on behalf of investors who purchased Avinger, Inc. ("Avinger") (NASDAQ:AVGR) securities pursuant and/or traceable to the Company’s Stock Offering on or about January 30, 2015.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/avinger?wire=3. There is no cost or obligation to you.
The complaint alleges that the Registration Statement and Prospectus filed for the Company’s Initial Public Offering contained materially false and misleading statements and/or failed to disclose that: (1) Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; (2) the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; (3) physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; (4) Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and (5) as a result, the Company was experiencing lower sales and revenues.
If you suffered a loss in Avinger contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/avinger?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
